A COLLABORATIVE
APPROACH TO IBD.

We are committed to fighting inflammatory diseases like IBD. But we’re not alone. We problem-solve across our global offices in 35 countries. We collaborate with external partners to develop innovative therapeutic approaches and aim to further advance the care of patients.

INTERNAL BIOMARKER
PROGRAM

We appreciate the complexities of inflammatory diseases and the difficulty healthcare professionals and patients face every day. Our internal biomarker program is helping us better understand what drives response to help improve outcomes for patients.

GILEAD AND
GALAPAGOS

In 2015, Gilead entered into a global partnership with Galapagos. In 2019, we further solidified our partnership, entering into a 10-year global research and development collaboration.

Using Galapagos’ unique platform, we’re utilizing disease-related, human primary cell–based assays to discover and verify novel drug targets.

OUR BACKGROUND IN INFLAMMATION.

Spleen tyrosine kinase (SYK) inhibition

2010

Gilead research efforts expand, evaluating spleen tyrosine kinase (SYK) inhibition and exploring treatments for inflammatory diseases

Gilead scientist evaluating Bruton’s tyrosine kinase (BTK) inhibitors

2014

Gilead and ONO partner to evaluate Bruton’s tyrosine kinase (BTK) inhibitors for B-cell malignancies and inflammatory diseases1

Galapagos building

2015

Gilead and Galapagos announce global collaboration to address inflammatory diseases2

Gilead CEO and Galapagos CEO shaking hands

2019

Gilead and Galapagos embark on a 10-year collaboration to discover and develop transformative therapies in inflammatory diseases3

References

REFERENCES 1. Data on file, 2014. 2. Data on file, 2015. 3. Data on file, 2019.

GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies.
© 2020 Gilead Sciences, Inc. All rights reserved.
UNBP5968 10/20